COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,617 Articles (22,913 medRxiv, 8,704 bioRxiv)

Most recent first Previous |  Page 1129: Articles 11281-11290  | Next

Modeling the trajectory of SARS-CoV-2 spike protein evolution in continuous latent space using a neural network and Gaussian process
King, S., Chen, X. E., Ng, S. W. S., Rostin, K., Roberts, T., Hahn, S. V., Schwab, J. C., Sekhon, P., Kagieva, M., Reilly, T., Qi, R. C., Salman, P., Hong, R. J., Ma, E. J., Hallam, S. J.
10.1101/2021.12.04.471198 — Posted: 2021-12-06
Investigation of Vaccine Breakthrough Infections by Vaccine strategy during the Delta Variant Wave in France
Bal, A., Destras, G., Simon, B., Giannoli, J.-M., Morfin-sherpa, F., Lina, B., josset, l.
10.1101/2021.12.05.21267301 — Posted: 2021-12-06
Predictions of the SARS-CoV-2 Omicron Variant (B.1.1.529) Spike Protein Receptor-Binding Domain Structure and Neutralizing Antibody Interactions
Ford, C. T., Jacob Machado, D., Janies, D. A.
10.1101/2021.12.03.471024 — Posted: 2021-12-06
Interactions of SARS-CoV-2 protein E with cell junctions and polarity PDZ-containing proteins
Zhu, Y., Alvarez, F., Wolff, N., Mechaly, A., Brule, S., Neitthoffer, B., Etienne-Manneville, s., Haouz, A., Boeda, B., Caillet-Saguy, C.
10.1101/2021.12.04.471219 — Posted: 2021-12-06
Critical Negatively Charged Residues Are Important for the Activity of SARS-CoV-1 and SARS-CoV-2 Fusion Peptides
Lai, A. L., Freed, J. H.
10.1101/2021.11.03.467161 — Posted: 2021-12-06
COVID-19 infections post-vaccination by HIV status in the United States
Coburn, S. B., Humes, E., Lang, R., Stewart, C., Hogan, B. C., Gebo, K. A., Napravnik, S., Edwards, J. K., Browne, L. E., Park, L. S., Justice, A. C., Gordon, K., Horberg, M. A., Certa, J. M., Watson, E., Jefferson, C. R., Silverberg, M. J., Skarbinski, J., Leyden, W. A., Williams, C. F., Althoff, K. N.
10.1101/2021.12.02.21267182 — Posted: 2021-12-06
Impact of COVID-19 on healthcare access for Australian adolescents and young adults
Islam, M. I., Freeman, J., Chadwick, V., Martiniuk, A.
10.1101/2021.12.01.21267121 — Posted: 2021-12-06
A kinetic model considering the decline of antibody level and vaccination of COVID-19
XU, C. q., Huang, X., Zhang, Z., Cui, J.
10.1101/2021.12.01.21266680 — Posted: 2021-12-05
A randomized clinical trial to stimulate the cholinergic anti-inflammatory pathway in patients with moderate COVID-19-pneumonia using a slow-paced breathing technique
Balint, E. M., Gruener, B., Haase, S., Kaw-Geppert, M., Thayer, J. F., Guendel, H. O., Jarczok, M. N.
10.1101/2021.12.03.21266946 — Posted: 2021-12-05
Using an electronic frailty index to predict adverse outcomes in geriatric COVID-19 patients: data from the Stockholm GeroCovid study
Mak, J. K. L., Eriksdotter, M., Annetorp, M., Kuja-Halkola, R., Kananen, L., Bostrom, A.-M., Kivipelto, M., Metzner, C., Back Jerlardtz, V., Engstrom, M., Johnson, P., Lundberg, L. G., Akesson, E., Suhl Oberg, C., Olsson, M., Cederholm, T., Hagg, S., Religa, D., Jylhava, J.
10.1101/2021.12.03.21267254 — Posted: 2021-12-05

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).